European countries in the race to attract successful biopharma investment: Winners and laggers.
Drug Discov Today
; 26(10): 2209-2213, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1375052
ABSTRACT
The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Industry
/
Pandemics
/
Drug Development
/
COVID-19
/
Investments
Type of study:
Prognostic study
Country/Region as subject:
Europa
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS